A Hundred Years of Insulin Innovation: When Science Meets Technology

Thomas Kjeldsen and Peter Kurtzhals

The story of insulin development is a remarkable example of what can be accomplished in medicine when academic science meets translational biotechnology. The foundation was laid 100 years ago this year with the discovery of insulin in Toronto in 1921, prompting a Nobel Prize in 1923.

The discovery made by Banting and Best (1) was so spectacular and of such importance for many people that it immediately led to collaboration with industry partners, most notably Eli Lilly in the U.S. and what became Novo Nordisk in Europe. One of the founding fathers of Novo Nordisk, Dr. August Krogh, was himself a Nobel Prize laureate. Krogh understood the scientific significance of the insulin discovery and partnered with people skilled in medicine as well as in technological development and upscaling. In the following decades, academic discoveries such as insulin crystallization (2) and binding of zinc (3) and protamine (4) immediately translated to benefits on insulin product characteristics that are of importance even today. Seminal discoveries in academia in the 1950s and 1960s unraveled the amino acid sequence as well as the secondary, tertiary, and quaternary insulin structures. These academic endeavors were led by Nobel Laureates Sanger (5) and Hodgkin (6), respectively. Another major milestone was Don Steiner's discovery that human insulin is produced as a single-chain proinsulin (7). The immunological characterization of proinsulin provided the technological background that allowed the pharmaceutical industry to refine the purification of insulin to obtain monocomponent insulin; this breakthrough lowered the risk of inducing an immune response in patients treated with insulin. The characterization of proinsulin and the realization that it could be converted into mature two-chain insulin by enzymatical treatment with trypsin and carboxypeptidase B led the way for industrial production of recombinant human insulin. Furthermore, in the 1990s, the first-generation long-acting basal insulin analog, insulin glargine (8), was designed by Hoechst, probably inspired by the proinsulin structure that carries the two arginine residues characteristic for glargine.

Alongside the breakthroughs in genetic engineering taking place through the 1970s involving both academia, biotech (Genentech, ZymoGenetics, Chiron Corporation), and industry (Eli Lilly, Hoechst AG and Company, and Novo Nordisk A/S), the fascinating structural elucidation of the insulin hormone both inspired and facilitated recombinant production of human insulin (9,10). Multiple tons of insulin are required yearly for treatment of people with diabetes, which simply would not be possible to supply without recombinant production. Identification of the insulin receptor (11) and the mapping of receptor binding surfaces (12) in the 1970s and 1980s were additional examples of academic discoveries of fundamental importance for future drug design.

Thus, at the time we joined the scientific insulin journey, the insulin molecule was structurally and pharmaceutically well characterized. At the same time, however, it was realized that human insulin in its native form was not perfectly suited for subcutaneous injection. Moreover, it was during the 1990s that the Diabetes Control and Complications Trial (DCCT) (13) and UK Prospective Diabetes Study (UKPDS) (14) provided evidence for the significance of intensive glucose control in reducing the risk of microvascular complications in people with both type 1 and type 2 diabetes, underscoring the clinical need for better insulin preparations to improve long-term patient outcomes.

It was hypothesized and later demonstrated that rational application of genetic engineering on the basis of structural insights would offer a possibility to tailor insulin analogs with optimized pharmacokinetic profiles. The first article on a rapid-acting insulin analog was a copublication between industrial and academic scientists, who had been contributing to resolving the X-ray structure of the insulin hexamer (15). There were long-standing and close contacts between scientists—industrial as well as

Novo Nordisk A/S, Bagsvaerd, Denmark

Corresponding author: Peter Kurtzhals, pkur@novonordisk.com

academic—with the common aim of improving insulin therapy. Hence, throughout the 1990s, the scientific environment was vibrant, collaborative, and competitive at the same time. However, it was the fatty acid acylation technology (16) that led to the next generations of basal insulin analogs and also proved to have the most far-reaching consequences beyond insulin into other areas of peptide drug delivery. This technology was inspired by the knowledge that albumin functions as an abundant carrier protein with immense capacity for fatty acids and drugs and that reversible acylation is used in nature for governing subcellular trafficking.

The fatty acid acylation technology provides an example of how scientific insights from the academic setting were applied to insulin discovery, prolonging the action profile for both daily (17) and weekly (18) administration. Intriguingly, a unique mechanistic dimension enabled by fatty acid acylation was applied to engineer insulin degludec, which is an ultra-long-acting insulin due to formation of multihexamers at the site of injection. Furthermore, the fatty acid acylation technology has provided a general approach to molecular engineering and pharmacokinetic protraction applicable to protraction of peptide drugs (19,20) and even to facilitation of oral peptide delivery (21–24). Thus, this principle was successfully utilized in the field of glucagon-like peptide 1 receptor agonists to design, for example, liraglutide, semaglutide, and tirzepatide and across other areas of protein-based therapy exemplified by the growth hormone analog somapacitan. The acylation technology is thus a recent example of a technology with a broad scope, first developed for insulin.

Taken together, we have been privileged to be part of a vibrant period of insulin innovation that illustrates the importance and strength of both academic and translational science, and we have seen that combined efforts have led to improved quality of life and life expectancy for people with diabetes.

References

1. Banting FG, Best CH. Pancreatic extracts. 1922. J Lab Clin Med 1990;115:254–272
2. Abel JJ. Crystalline insulin. Proc Natl Acad Sci U S A 1926;12:132–136
3. Scott DA. Crystalline insulin. Biochem J 1934;28:1592–1602
4. Hagedorn HC, Jensen BN, Krarup NB, Wodstrup I. Protamine insulinate. J Am Med Assoc 1936;106:177–180
5. Sanger F, Tuppy H. The amino-acid sequence in the phenylalanyl chain of insulin. 1. The identification of lower peptides from partial hydrolysates. Biochem J 1951;49:463–481
6. Adams MJ, Blundell TL, Dodson EJ, et al. Structure of rhombohedral 2 zinc insulin crystals. Nature 1969;224:491–495
7. Steiner DF, Cunningham D, Spigelman L, Aten B. Insulin biosynthesis: evidence for a precursor. Science 1967;157:697–700
8. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644–649
9. Goeddel DV, Kleid DG, Bolivar F, et al. Expression in *Escherichia coli* of chemically synthesized genes for human insulin. Proc Natl Acad Sci U S A 1979;76:106–110
10. Thim L, Hansen MT, Norris K, et al. Secretion and processing of insulin precursors in yeast. Proc Natl Acad Sci U S A 1986;83:6766–6770
11. Ullrich A, Bell JR, Chen EY, et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 1985;313:756–761
12. Pullen RA, Lindsay DG, Wood SP, et al. Receptor-binding region of insulin. Nature 1976;259:369–373
13. Nathan DM, Genuth S, Lachin J, et al.; Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986
14. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–865
15. Brange J, Ribel U, Hansen JF, et al. Monomeric insulins obtained by protein engineering and their medical implications. Nature 1988;333: 679–682
16. Kurtzhals P, Havelund S, Jonassen I, et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 1995;312:725–731
17. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012;29:2104–2114
18. Rosenstock J, Bajaj HS, Janež A, et al.; NN1436-4383 Investigators. Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med 2020;383:2107–2116
19. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne) 2019;10:155
20. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab 2018;18:3–14
21. Kjeldsen TB, Hubálek F, Tagmose TM, et al. Engineering of orally available, ultralong-acting insulin analogues: discovery of OI338 and OI320. J Med Chem 2021;64:616–628
22. Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med 2018;10:eaar7047
23. Hubálek F, Refsgaard HHF, Gram-Nielsen S, et al. Molecular engineering of safe and efficacious oral basal insulin. Nat Commun 2020;11:3746
24. Husain M, Birkenfeld AL, Donsmark M, et al.; PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019;381:841–851